The increased co-expression of SLC7A11 and PD-L1 was associated with poor prognosis in extranodal natural killer T-cell lymphoma patients
Two cancer pathways working together predict worse outcomes in rare lymphomas, suggesting combination therapy targeting both might overcome drug resistance.
In 42 ENKTL patients, high co-expression of SLC7A11 and PD-L1 in CD56+ neoplastic cells was significantly associated with worse OS and PFS, with findings validated in an independent GEO dataset. The co-localization of ferroptosis-resistance (SLC7A11) and immune checkpoint (PD-L1) pathways suggests dual-targeted therapy may overcome primary resistance to checkpoint inhibition in this aggressive rare lymphoma.
What the study was
- Study design
- Retrospective cohort prognostic study with IHC (n=42 ENKTL) and external validation (GSE90597)
- Population
- 42 ENKTL patients (IHC cohort); GSE90597 external validation cohort
- Sample size
- 42
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Cancer Immunol Immunother
Why it surfaced
Novel biomarker study in ultra-rare ENKTL identifying SLC7A11/PD-L1 co-expression as a poor-prognostic marker with therapeutic implication; external GEO validation improves confidence despite small n=42.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.